Diamyd Medicals vd har köpt aktier i Bolaget
April 28, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att vd Ulf
Hannelius har köpt 20 000 B-aktier i Diamyd Medical.
- Diamyd Medical befinner sig i en spännande fas och det är både...
Diamyd Medical’s CEO purchases shares in the Company
April 28, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that CEO Ulf Hannelius has purchased 20,000 Series B shares in Diamyd Medical.
“Diamyd Medical is in an exciting phase and...
Delresultat från DIAGNODE-1 pekar mot en tydlig och eftersträvad ombalansering av immunförsvaret vid administration av Diamyd® direkt i lymfkörtel
April 21, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar att professor
Johnny Ludvigsson presenterar preliminära immunologiska delresultat från fyra
patienter i pilotstudien DIAGNODE-1 vid...
Interim results from DIAGNODE-1 indicate clear and desired re-balancing of the immune system after administration of Diamyd® directly into lymph nodes
April 21, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that Professor Johnny Ludvigsson will present preliminary immunological interim
results from four patients in the pilot...
Diamyd Medical increases strategic investment in the stem cell company Cellaviva
April 20, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that the Company has increased its investment in the associated company
Cellaviva AB with an additional SEK 1.3 million....
Diamyd Medical ökar strategisk investering i stamcellsbolaget Cellaviva
April 20, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att Bolaget
ökat sin investering i Cellaviva AB med ytterligare 1,3 miljoner kronor.
Investeringen är gjord inom ramen för ett...
Diamyd Medical appoints new CEO
April 11, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that the Company’s Board of Directors has appointed Ulf Hannelius, PhD, MBA, to
new CEO.
Ulf Hannelius (40), PhD in...
Diamyd Medical utser ny verkställande direktör
April 11, 2016 02:30 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att Bolagets
styrelse utsett Ulf Hannelius PhD, MBA, till ny verkställande direktör.
Ulf Hannelius, 40 år, filosofie doktor i...
Diamyd Medical is engaged in discussions regarding an extension of GABA/Diamyd® trial in Birmingham, Alabama
April 06, 2016 02:32 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced in
its second quarterly report for the fiscal year 2015/2016 that the Company is
engaged in discussions regarding an...
Diamyd Medical för diskussioner om utökning av GABA/Diamyd®-studie i Birmingham, Alabama
April 06, 2016 02:32 ET
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag i sin andra
kvartalssrapport för räkenskapsåret 2015/2016 att Bolaget för diskussioner om
att utöka den pågående...